drugset / Trial / NCT02205489

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

NCT02205489

Phase 4 Completed 58 enrolled Genzyme, a Sanofi Company
NaSingle-groupOpen-labelTreatment

Summary

Primary Objective: To assess the distribution of IARs by severity grade when LEMTRADA is administered to RRMS patients who will be medicated according to specified algorithm designed to manage infusion associated reactions.

Timeline

Start
2014-10
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Alemtuzumab Monoclonal antibody Intravenous
Background Acetaminophen Small molecule Oral
Background Acyclovir Small molecule Oral
Background Cetirizine Other / unclassified Oral
Background Esomeprazole Small molecule Oral
Background Ibuprofen Small molecule Oral
Background Methylprednisolone Other / unclassified Oral
Background Ranitidine Unknown Oral